![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Krüppel-like factor 4 (KLF4) is expressed in a variety of tissues with diverse physiological functions and activities. KLF4 can also function as a tumor suppressor or an oncogene, depending on the cellular context. Its role in hematological malignancies is controversial. This study examined the expression levels of KLF4 by immunohistochemistry in 73 pediatric non-Hodgkin lymphomas (NHLs) in a tissue microarray and also on several B-NHL cell lines. Elevated levels of KLF4 expression were detected in 66% of lymphoma cases and were more frequent in the Burkitt lymphoma (p = 0.05) subtype. There was a significant predictive power for outcome with low KLF4 expression, predicting a favorable overall survival compared to high levels. Multivariate analyses confirmed the association of KLF4 expression with unfavorable overall survival (p < 0.005). These findings were consistent with analyses in existing NHL microarray datasets. The present findings revealed that KLF4 is overexpressed in Burkitt pediatric lymphoma and is a potential biomarker for inferior overall survival.
Keywords::
Acknowledgements
The authors acknowledge the assistance of Melissa Cao in the preparation of the manuscript.
Potential conflict of interest
Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.
This study was supported in part by academic support from SEP-CONACYT, Mexico (MIV CB-2011-01, 169368) and Grant FIS/IMSS/PROT/G10/837 from the IMSS (M.I.V.), UC MEXUS-CONACYT (M.I.V. and O.M.-M., Collaborative Research Grants CN-11-554), CONACYT (A.H.-V., M.H.-A., G.G.V.), Jonsson Comprehensive Cancer Center (M.I.V.), UCLA AIDS Institute (M.I.V.) and a Fogarty International Center Fellowship (D43 TW00013-14) (M.I.V. and S.H.-Y.). This study was also supported by various donors (B.B.) and by the Johnson Comprehensive Cancer Center at UCLA (B.B.).